Meeting
Abstract Number: 111
Hospital Medicine 2020, Virtual Competition
Background: Factor concentrates such as 4 factor-prothrombin complex concentrate (4F-PCC) are commonly used off-label as reversal agents in factor Xa inhibitor-associated bleeding events. However, there have been limited studies on the efficacy and safety of 4F-PCC use in these settings. We conducted a retrospective observational study of the use of 4F-PCC for major bleeding occurring […]
Abstract Number: 156
Hospital Medicine 2018; April 8-11; Orlando, Fla.
Background: While anticoagulants are the core treatment plan for preventing strokes in patients with atrial fibrillation and managing patients with thromboembolic disease, there is a dichotomy of efficacy and harm with their use. Rapid inpatient reversal protocols are important for patient safety. Four factor prothrombin complex concentrate (4FPCC) is approved for reversal of warfarin-induced coagulopathy. […]